COMMON PATIENT ASSISTANCE PROGRAM APPLICATION (HIV) 1/3

PROGRAM DESCRIPTION

The purpose of this enrollment tool is to collect information that numerous pharmaceutical companies and foundations providing the donated products of pharmaceutical companies require for enrollment in various HIV patient assistance programs (PAPs). These PAPs provide medicines at little or no cost to eligible patients. To facilitate enrollment in multiple PAPs, this tool consolidates all of the necessary information in one place. In each instance in which the tool refers to "PAPs" it means all of the PAPs for which the applicant may be eligible. **Each PAP will determine a patient's eligibility for assistance based on their individual program requirements**.

PATIENT GENERAL INFORMATION

Name (First):	(Middle):				(Last):			
Mailing Address:				City:		State:	Zip:	
Phone:	Ok to call?	E-mail (optio	nal)		_ Language: C	English O Spanis	h O Other: _	
Gender: O M O F Date of bi	rth:	_ Number in	Household (circle	e): 1 2 3 4	56789	Current Annual Ha	usehold Income: S)
COVERAGE INFORMATION	(check all that app	ly)						
□AIDS Drug Assistance Program:	O Enrolled	O Denied	O Pending	O Not Applied	🔿 Not Eligible	O Waitlisted		
□ Medicaid:	O Enrolled	O Denied	O Pending	O Not Applied	O Not Eligible	•		
□ Medicare:	O Enrolled	O Denied	O Pending	O Not Applied	O Not Eligible	•		
Medicare Part D:	O Enrolled	O Denied	O Pending	O Not Applied	O Not Eligible)		
Private Insurance Drug Coverage	e 🗆 VA	🗆 Othe	r:					
PHYSICIAN/PRESCRIBER INFORMATION								
Name (First):		(Mi	ddle):			(Last):		
Business/Facility Name:				Phone:	:		_ Fax:	
Office Contact Name (First):				(M.I.):		(Last):		
Mailing Address:				City:		State	e: Zip	:
Professional Designation/Specialty	National Provid				tional Provider Ide	entifier:		
Tax ID #:		DEA	#:			State License #:		
ALTERNATE SHIPPING INFORMATION (some PAPs require medication to be shipped to physician/prescriber while others will ship to the patient's alternate shipping address of choice)								
Name (First):		(Mi	ddle):			(Last):		
Business/Facility Name:				Phone:	:		_ Fax:	
Shipping Address:				City:		Stat	e: Zij):
Relationship to patient:								
Reason for alternate:								
ADVOCATE INFORMATION	(if applying on beh	alf of patient)						
Name (First):		(Mi	ddle):			(Last):		
Business/Facility Name:		Phone:			:	Fax:		
Street Address:				City:		Stat	e: Zij):
Relationship to patient:								
Advocate Signature						Date		

This tool was developed with the assistance of the Department of Health and Human Services/Health Resources and Services Administration.

COMMON	PATIENT ASSISTAN	NCE PROGRAM APPLICATIO	ON (HIV) Tool 2/3	
Abbott Patient Assistance Foundation 20. Box 270, Somerville, NJ 08876 — Phone: 800-222-6885 Fax: 866-483-1305		*If there is a need for an urgent delivery of medication, the health care provider should call the program directly to discuss options.	App. submitted via: OFax OMail OShip to Physician	
Kaletra® (lopinavir/ritor Norvir® (ritonavir)		**Original "ink" signature required to complete enrollment. No stamped signatures are accepted.	Attachment Req.: 6 If insured but cannot afford treatment: 4 & 5	
Boehringer Ingelheim Car Patient Assistance Program P.O. Box 66565, St. Louis, MO 6310	res Foundation Inc. c/o Express Scripts SDS, Inc. 56 — Phone: 800-556-8317 Fax: 800-639-9118	*Once an application is received, the patient can expect to receive medicine within 48 hours.	App. submitted via: OFax OMail OShip to Provider Attachment Reg.: 2; 5 if Part D enrollee	
□ Aptivus® (tipranavir) □ Viramune XR® (nevira	pine)			
Bristol-Myers Squibb Acce 6900 College Boulevard, Suite 1000 Phone: 888-281-8981 Fax: 888-28	ess Virology Patient Assistance Program 1, Overland Park, KS 66211 31-8985	*Original "ink" signature required to complete enrollment. No stamped signatures are accepted.	App. submitted via: OFax OMail Attachment Req.: 1, 2 or 3; 4 & 5	
Reyata [®] (atazanavir sul	fate)			
Bristol-Myers Squibb & Gilead Sciences, LLC Atripla Patient Assistance Program P.O. Box 13185, La Jolla, CA 92039 — Phone: 866-290-4767 Fax: 866-290-4487		*Patients that are pre-screened and determined to be eligible for the program may receive a voucher for the immediate pickup of a 30-day supply at the pharmacy of their choice.	App. submitted via: OFax OMail Attachment Req.: 1, 2 & 3	
	ricitabine/tenofovir disoproxil fumarate)	**Original "ink" signature required to complete enrollment. No stamped signatures are accepted.	Anuchinen Keq., 1, 2 & 3	
Gilead Advancing Access:	Reimbursement Solutions for Patients in Need — Phone: 800-226-2056 Fax: 800-216-6857	*Immediate access is available for all products except Vistide and Hepsera.	App. submitted via: OFax OMail	
		Patients that are pre-screened and determined to be eligible for the program may receive a voucher for the immediate pick-up of a 30-day supply at the pharmacy of their choice.	Attachment Req.: 1, 2 & 3	
Emtriva® (emtricitabine) Emtriva Oral Solution Hepsera® (adefovir dipin)	**Original "ink" signature required to complete enrollment. No stamped signatures are accepted.		
Truvada [®] (emtricitabine Viread [®] (tenofovir disop	oxil fumarate) 300mg	*This Program has an emergency shipment process for patients that are in jeopardy of experiencing an interruption in therapy. This is a 24-hour turnaround to provide medication directly to the patient's home. These are made on exception basis only and approval is a result of discussions between the Program and the patient or physician.	App. submitted via: ○Fax ○Mail ○ Ship to Provider ○ Ship to Patient	
Viread® (tenofovir disop Vistide® (cidofovir injecti	on)	**Merck requires both original "ink" signed enrollment tool and "ink" signed doctor prescription. No copies or stamps are accepted. If the tool is started by	Attachment Req.: 6 & 7	
Merck SUPPORT TM Program P.O. Box 305, San Bruno, CA 94066 — Phone: 800-850-3430 Fax: 866-410-1913 Crixivan [®] (indinavir sulfate) Isentress [®] (raltegravir)		fax, the patient must follow up by mailing in the original enrollment process and prescription. ***This Program does not accept an advocate signature on behalf of the patient.		
Johnson & Johnson Patient Assistance Foundation, Inc. P.O. Box 221857, Charlotte, NC 28222 — Phone: 800-652-6227 Fax: 888-526-5168 Edurant® (rilpivirine) Is the patient currently taking?		*Immediate access is available through the use of pharmacy card. At the	App. submitted via: OFax OMail	
		request of the physician, a pharmacy card number will be provided to the potient ONLY, immediately upon eligibility approval. He/she can then go to the pharmacy to pick up their medicine.	O Pharmacy Card (Pick Up) O Ship to Physician	
□ Intelence [®] (etravirine) □ Prezista [®] (darunavir)	Is the patient currently taking?Is the patient currently taking?		Attachment Req.: 2, 4 & 6 Prescription only needed if drug is shipped to physician	
ViiV Healthcare Patient Assistance Program P.O. Box 52037, Phoenix, AZ 85072 — Phone: 877-784-4842 Fax: 877-784-4004 COMBIVIR® (lamivudine/zidovudine) EPIVIR® (lamivudine) EPZICOM® (abacavir sulfate and lamivudine)		*Patients who need medicine that same day must have an Advocate (i.e., anyone involved in the delivery of the patient's healthcare) enroll them by phone. Same day access is not available for Medicare Part D participants. Patients eligible for same day access can pick up the medicine at any retail	App. submitted via: O Fax O Mail	
		pharmacy with a valid prescription. They can get up to two fills at a local pharmacy when they initially enroll. There is a \$10 co-pay per retail fill at a	O Phone (for immediate access by an advocate)	
		pharmacy. The Advocate must also sign the application in the Advocate Information section when enrolling the patient for same day access.	O Pharmacy Pick-Up (if immediate access required and approved via phone by an advocate)	
LEXIVA® (fosamprenavir		**Medicare Part D participants must have spent \$600 out of pocket on prescription drugs during the current calendar year (as one of the eligibility criteria) to qualify for assistance.	Attachment Req.: 1, 2, and/or 3; 6; 4 & 5 if Part D enrollee	
RETROVIR® (zidovudine) SELZENTRY® (maraviroc) TRIZIVIR® (abacavir sulfate, lamivudine, and zidovudine)		***Original "ink" signature required to complete enrollment. No stamped signatures are accepted.		
□ VIRACEPT® (nelfinavir n	nesylate)			
ZIAGEN® (abacavir sulfa	te)			
ATTACHMENTS: (requirements vary by program)	 Copy of recent paystub Copy of first page of most recent Federal income to 3. Copy of social security check or awards letter 	tax return 5. Copy of drug receipts (if Part D or insured) any k	yy & Health Information: list of nown drug allergies and 1t medications	

IMPORTANT: Send completed Common Patient Assistance Program Applications to the corresponding addresses listed for each company.

COMMON PATIENT ASSISTANCE PROGRAM APPLICATION (HIV) Tool 3/3 PATIENT AUTHORIZATION

By my signature, I authorize each Program and their agents to do the following:

- 1. Use any information that I provide in my application for the purpose of enrolling in or to administer the PAPs;
- 2. Contact my doctor, healthcare provider, or pharmacist about my application for the PAPs, and disclose to them information contained in my application, in order to help me receive Programs' products under the PAPs and ensure that PAPs' guidelines are being met;
- Request information from my insurer, doctor, healthcare provider, or pharmacist about the prescribed medications I receive or will receive under the PAPs and about my medical condition. This information will be used only to determine my eligibility for the PAPs and to administer the PAPs. By signing below, I also authorize my insurer, doctor, healthcare provider, or pharmacist to release information about my prescribed medications and medical condition that is requested by Programs or their agents;
- 4. Contact my insurer, other potential funding sources, including the Centers for Medicare and Medicaid Services, social workers or patient advocacy organizations on my behalf in order to determine if I am eligible for health insurance coverage or other funds, and disclose to them information contained in my PAP applications or information about my prescribed medications and medical condition that has been provided by my physician, healthcare provider or pharmacist; and
- 5. Disclose any information obtained from the sources listed above to third parties if required by law.

By my signature, I am signifying that I understand the following:

- 1. Once medical information about me has been disclosed in reliance upon this Authorization, the information may no longer be protected by federal privacy laws and may be further disclosed; however, Programs agree to protect my information by using and disclosing it only for the purposes described above or as required by law.
- 2. Programs and their agents will only ask for the information that is needed to process my application, renew my application or provide me with help throughout my Program participation. Each Program will only have access to the information needed for that Program and will not have access to information required for enrollment in any other PAP.
- 3. This Authorization will remain in effect for as long as I participate in the Program and a period of 5 years after my participation in the Program ends, and that I am entitled to request a copy of this signed Authorization.
- 4. I have the right to revoke this authorization at any time by mailing a signed written statement of my revocation to the address(es) used on page 1. Such a revocation would end my eligibility to participate in the PAPs. Revoking this authorization will prohibit disclosures after the date written revocation is received, except to the extent that action has been taken in reliance on my authorization.
- 5. Any assistance in the form of product at no cost is contingent upon my ability to meet the eligibility criteria for the Program.
- 6. The program assistance may change or be discontinued at any time without any notice to me.
- 7. I agree that the Program does not have any liability in providing PAP services to me.

Finally, I understand I may refuse to sign this authorization and that if I refuse, my eligibility for health plan benefits and treatment by my doctor will not change, but I will not have access to the services available through this program.

If I receive any free product from Programs, I certify that I will not seek reimbursement from any public or private prescription drug plan for the use of such product.

I certify that the information in this application is complete and accurate to the best of my knowledge and agree to notify PAPs of any change in my insurance eligibility or financial status within 30 days by providing that information to the address(es) used on page 1.

Signature (Patient or Legal Representative)

Date

PHYSICIAN/PRESCRIBER CERTIFICATION

By my signature, I certify:

- 1. To the best of my knowledge, the information on this patient is correct and complete and consistent with applicable privacy laws and regulations, and I understand that Program and/or their agents are relying on this representation.
- 2. I have no knowledge of any intent to sell, barter or give this product to any person other than the patient for whom it has been prescribed.
- 3. No reimbursement of the cost of product will be accepted by me from public or private sources, including patients, for any treatments where product will be provided free-of-charge by Program.
- 4. The medication(s) covered by the PAPs are medically indicated for this patient and that I will be supervising the patient's treatment.
- 5. I agree to periodically verify continued use of Programs' medication and resubmit current prescriptions.
- 6. My State license is currently in good standing, I am not prohibited from participating in Federally-funded health care programs, nor am I on the List of Excluded Individuals/Entities maintained by the HHS Office of Inspector General.

I authorize the Program to forward this prescription to a dispensing pharmacy on behalf of myself and my patient, or to send the medication directly to the patient, or to send the medication to my office for dispensing to my patient in accordance with individual program requirements.